Application No.: NEW Docket No.: 0760-0347PUS1

AMENDMENTS TO THE CLAIMS

1. (Original) A vector for gene therapy comprising an expression vector for mammalian cells and a nucleic acid coding for a fusion protein of glucagon C-terminal side 19-29 amino acid peptide region and a desired protein region which should be produced in the body, which vector can produce said fusion protein in the mammalian cells.

- 2. (Original) The vector according to claim 1, wherein said glucagon C-terminal side 19-29 amino acid peptide region is ligated to the C-terminal of said desired protein region.
- 3. (Original) The vector according to claim 1 or 2, wherein said desired protein is a cytokine, a fusion protein comprising a cytokine and a constant region of immunoglobulin ligated to said cytokine, a growth factor, a hormone or a cell adhesion factor, or a receptor thereof.
- 4. (Original) The vector according to claim 3, wherein said cytokine or the receptor thereof is selected from the group consisting of interferons and receptors thereof, CTLA4, interleukins and receptors thereof.
- 5. (Currently Amended) A method for gene therapy comprising administering an effective amount of said vector for gene therapy according to any one of claims 1 to 4 claim 1 to a mammal or cultured mammalian cells, in which expression of said desired protein in the body or in the cultured mammalian cells is desired.

2 GMM/nl

Application No.: NEW Docket No.: 0760-0347PUS1

6. (Currently Amended) The method according to claim_5, wherein said vector for gene therapy is administered to a mammal.

- 7. (Currently Amended) Use of the vector for gene therapy according to any one of claims 1 to 4 claim 1 for the production of a drug for gene therapy.
- 8. (Currently Amended) A method for quantifying a desired protein produced in the body or in cultured cells by expression of said vector for gene therapy, comprising quantifying, by immunoassay, said glucagon C-terminal side 19-29 amino acid peptide region in a test sample collected from a mammal or cultured mammalian cells to which said vector for gene therapy according to any one of claims 1 to 4 claim 1 was administered.
- 9. (Original) The method according to claim 8, wherein said test sample is collected from said mammal to which said vector for gene therapy was administered.
- 10. (Original) The method according to claim 9, wherein said test sample is a blood sample.
- 11. (Original) A label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, consisting essentially of glucagon C-terminal side 19-29 amino acid peptide.

3 GMM/nl

12. (Original) A label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal, consisting essentially of glucagon C-terminal side 19-29 amino acid peptide.

- 13. (Original) A method for labeling a protein produced in the body or in cultured cells, comprising labeling a desired protein produced in the body or in cultured cells with glucagon C-terminal side 19-29 amino acid peptide by expressing said desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, as a fusion protein with said glucagon C-terminal side 19-29 amino acid peptide as a label.
- 14. (Original) The method according to claim 13, comprising labeling said desired protein produced in the body with glucagon C-terminal side 19-29 amino acid peptide by expressing said desired protein produced by expression of an externally administered expression vector in the body of a mammal, as a fusion protein with said glucagon C-terminal side 19-29 amino acid peptide as a label.
- 15. (Original) Use of glucagon C-terminal side 19-29 amino acid peptide as a label for a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells.

Application No.: NEW Docket No.: 0760-0347PUS1

16. (Original) Use of glucagon C-terminal side 19-29 amino acid peptide as a label for a desired protein produced by expression of an externally administered expression vector in the body of a mammal.

5 GMM/nl